OnKure Therapeutics, Inc. (OKUR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.95 (-0.34%), Market cap $0.06B, 52-week low–high $1.83 ~ $4.59.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Financial statements, price targets, institutional (13F) holdings and related news for OnKure Therapeutics, Inc. are updated in real time on BlackAll Trade.
OnKure Therapeutics, Inc. trades at $2.95 (-0.34%). Real-time quotes and charts are available on BlackAll Trade.
OnKure Therapeutics, Inc. has a market cap of about $0.06B.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other d